Adjunctive everolimus for children and adolescents with treatment-refractory seizures associated with tuberous sclerosis complex: post-hoc analysis of the phase 3 EXIST-3 trial


Curatolo P., Franz D. N. , Lawson J. A. , Yapici Z. , Ikeda H., Polster T., ...More

LANCET CHILD & ADOLESCENT HEALTH, vol.2, no.7, pp.495-504, 2018 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 2 Issue: 7
  • Publication Date: 2018
  • Doi Number: 10.1016/s2352-4642(18)30099-3
  • Journal Name: LANCET CHILD & ADOLESCENT HEALTH
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Page Numbers: pp.495-504

Abstract

Background Epilepsy occurs in 70-90% of patients with tuberous sclerosis complex. We aimed to assess the efficacy and safety of adjunctive everolimus for treatment-refractory seizures associated with tuberous sclerosis complex in paediatric patients enrolled in the EXIST-3 trial, a double-blind, placebo-controlled, randomised, phase 3 study.